Venus Remedies says it has secured Argentina marketing approval for Ceftriaxone, a key antibiotic used to treat serious bacterial infections. The authorization is a major milestone in the company’s Latin America expansion, with Argentina highlighted as an important market for critical care therapies. The move strengthens Venus Remedies’ international presence and its focus on more accessible anti-infective treatments.
Doctors worldwide are confronting hospital-acquired “superbugs” fueled by antimicrobial resistance (AMR). The threat is stark: about 5 million deaths occur each year, yet clinicians still face limited tools to stop infections when standard antibiotics stop working. With bacteria evolving faster than new drugs, hospitals are bracing for a wider, more lethal antimicrobial crisis.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Veterinary experts say chicken and eggs remain affordable, reliable sources of protein, while warning that viral misinformation is damaging the poultry sector. They address public fears around hormones, antibiotics, and bird flu, stressing that steroid hormone implants are not approved for poultry growth. They also point to steady growth in India’s egg and poultry meat production driven by genetics, feed, health, and management.
Orchid Pharma, once abandoned by investors, is hitting a major milestone with its first novel antibiotic drug. The company outlicensed the experimental therapy to Germany’s Allecra Therapeutics, which has now secured crucial approvals from the US FDA and a European drug regulator. Developed by Indian scientists in 2008, the breakthrough aims to strengthen the global fight against bacterial infections.
Habil Khorakiwala’s turnaround of Wockhardt began amid near bankruptcy, including payment defaults to bondholders and troubled manufacturing units. After surviving the company’s worst crises, the focus has shifted to a single blockbuster antibiotic drug hailed as the biggest breakthrough after penicillin. If it scales, Khorakiwala could re-enter the top league again.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
